



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



# شبكة المعلومات الجامعية

## التوثيق الالكتروني والميكرو فيلم

# جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأفلام قد اعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of  
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



# بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية



بالرسالة صفحات  
لم ترد بالأصل

**THE PROTECTIVE EFFECT OF AN ISOTHIOCYANATE  
PRODRUG AGAINST CHROMOSOMAL ABERRATIONS  
INDUCED BY SOME MUTAGENIC DRUGS IN MICE**

**A THESIS**

**Submitted in Partial Fulfillment  
of the requirement for Degree of (Ph. D) in  
Science (Zoology)  
(Genetics)**

**By**

**AZIZA MOHAMED MAHMOUD HASSAN**

**B. Sc. & M.Sc.**

**Faculty of Science, Zoology, Cairo University**

**Supervisors**

**Prof. Dr. Zainab A. El-Baih**

Zoology Department  
Faculty of Science  
Cairo University

**Prof. Dr. Essam El Nahass**

Cell Biology Laboratory  
National Research Center

**Prof. Dr. Samia A. El-Fiky**

Cell Biology Laboratory  
National Research Center

B

1-ΛΛε

**Department of Zoology  
Faculty of Science  
Cairo University  
2000**


بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿ وَقُلْ رَبِّیْ زِدْنِیْ عِلْمًا ﴾

صدق الله العظيم

سورة طه

آیه (۱۱۴)



TO  
MY MOTHER, MY HUSBAND  
AND  
MY KIDS  
YASSEN & YASSMIN

## **AKNOWLEDGEMENT**

In actual fact, prayerful thanks, at first to our merciful *God* who gives me every thing I hope.

I would like to express my grateful thanks to *Prof. Dr. Zainab A. El-Baih*, Zoology Department, Faculty of Science, Cairo University for her keep supervision, offering the facilities and continuous encouragement.

My sincere gratitudes should be offered to *Prof. Dr. Essam El-Nahas*, Professor of Embryo technology and Cytogenetics, National Research Center for his constant support and careful guidance throughout the course of this work and generous supervision.

I would like to express my deep sense of gratitude to *Prof. Dr. Samia A. El-Fiky*, Professor of Cytogenetics, National Research Centre for suggesting the research point, prudent advices and kind continuous supervision.

I owe a heavy debt of gratitude to *Prof. Dr. Bassem El-Menshawy*, Professor of Pharmacognosy, Pharmacognosy

**Department, National Research Center, for his careful guidance unlimited help and making available all facilities for carrying out this work.**

**For *Dr. Karima, F. Mahrous, Assistance Professor of Cytogenetics*, National Research Center, no words can satisfy and explain my deep feeling of gratitude for her help, advice, kind continuous supervision and encouragement during the course of this work.**

**My profound gratitude to my *family and my husband*, no words can satisfy and explain my deep feeling of gratitude. Without his help and encouragement, this study would have never been completed.**

**Finally I wish to thanks all of cell biology laboratory.**

# TABLE OF CONTENTS

|                                              | Page      |
|----------------------------------------------|-----------|
| <b>I- INTRODUCTION -----</b>                 | <b>1</b>  |
| <b>II- REVIEW OF LITERATURE -----</b>        | <b>4</b>  |
| II-1- Mutagenicity -----                     | 5         |
| II-2- Mutagens and carcinogens -----         | 5         |
| <i>a- Benzo(a)pyrene -----</i>               | <i>9</i>  |
| <i>b- Cyclophosphamide -----</i>             | <i>11</i> |
| <i>c- Mitomycin C. -----</i>                 | <i>12</i> |
| II-3- Chemoprevention of cancer -----        | 14        |
| II-4- Antimutagens and anticarcinogens ----- | 16        |
| <i>1- Bio antimutagens -----</i>             | <i>17</i> |
| <i>2- Desmutagens -----</i>                  | <i>18</i> |
| II-5- Isothiocyanate -----                   | 22        |
| II-6- Cytogenetic end points -----           | 25        |
| <i>1- Micronucleus test -----</i>            | <i>25</i> |
| <i>2- Chromosomal aberrations -----</i>      | <i>27</i> |
| <i>3- Sperm abnormality -----</i>            | <i>30</i> |

|                                                           |           |
|-----------------------------------------------------------|-----------|
| <b>III- MATERIALS AND METHODS -----</b>                   | <b>32</b> |
| III-1- Drugs -----                                        | 32        |
| <i>1-1- Protector -----</i>                               | <i>32</i> |
| <i>1-2- Mutagenic drugs -----</i>                         | <i>32</i> |
| III-2- Animals -----                                      | 33        |
| III-3- Experimental design -----                          | 34        |
| III-4- Protocols for studied cytogenetic end point -----  | 36        |
| <i>4-1- Micronucleus assay -----</i>                      | <i>36</i> |
| <i>4-2- Chromosomal aberrations -----</i>                 | <i>37</i> |
| <i>4-3- Mitotic activity -----</i>                        | <i>41</i> |
| <i>4-4- Sperm abnormality -----</i>                       | <i>41</i> |
| III-5- Statistical analysis -----                         | 43        |
| <b>IV- RESULTS -----</b>                                  | <b>44</b> |
| IV-A- Micronucleus study -----                            | 44        |
| IV-B- Chromosomal aberrations -----                       | 50        |
| <i>1- In somatic cells (bone marrow and spleen) -----</i> | <i>51</i> |
| <i>2- In germ cells (spermatocytes) -----</i>             | <i>70</i> |
| IV-C- Sperm abnormality study -----                       | 82        |
| <b>V- DISCUSSION -----</b>                                | <b>87</b> |

|                                  |            |
|----------------------------------|------------|
| <b>VI- SUMMARY -----</b>         | <b>107</b> |
| <b>VII- REFERENCES -----</b>     | <b>111</b> |
| <b>IIX- ARABIC SUMMARY -----</b> | <b>1</b>   |

## List of tables

| Table No. | Title                                                                                                                                           | Page |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1         | Effect of benzylisothiocyanate-prodrug on Benzyo(a)Pyrene, Cyclophosphamide and Mitomycin C induced micronuclei In bone marrow of mice          | 48   |
| 2         | Effect of benzylisothiocyanate-prodrug on Benzyo(a)Pyrene induced chromosomal aberrations in bone marrow of mice                                | 57   |
| 3         | Effect of benzylisothiocyanate-prodrug on Benzyo(a)Pyrene induced chromosomal aberrations in spleen cells of mice                               | 58   |
| 4         | Effect of benzylisothiocyanate-prodrug on Cyclophosphamide induced chromosomal aberrations in bone marrow of mice                               | 60   |
| 5         | Effect of benzylisothiocyanate-prodrug on Cyclophosphamide induced chromosomal aberrations in spleen cells of mice                              | 61   |
| 6         | Effect of benzylisothiocyanate-prodrug on Mitomycin C induced chromosomal aberrations in bone marrow of mice                                    | 63   |
| 7         | Effect of benzylisothiocyanate-prodrug on Mitomycin C induced chromosomal aberrations in spleen cells of mice                                   | 64   |
| 8         | Effect of benzylisothiocyanate-prodrug (BITC-p) on mitotic activity in mice bone marrow cells treated with mutagenic drugs (BaP, C. P. and MMC) | 68   |
| 9         | Effect of benzylisothiocyanate-prodrug on Benzyo(a)Pyrene induced chromosomal aberrations in spermatocytes of mice                              | 76   |
| 10        | Effect of benzylisothiocyanate-prodrug on Cyclophosphamide induced chromosomal aberrations in spermatocytes of mice                             | 78   |
| 11        | Effect of benzylisothiocyanate-prodrug on Mitomycin C induced chromosomal aberrations in spermatocytes of mice                                  | 80   |
| 12        | Inhibitory effect of highest dose of benzylisothiocyanate on Benzyo(a)Pyrene induced abnormal sperm in mice                                     | 85   |

## List of figures

| Figure No. | Title                                                                                                                                                       | Page |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1          | Histogram showing the effect of BITC-p on BaP, C.P and MMC induced micronuclei in bone marrow of mice                                                       | 49   |
| 2          | Histogram showing the effect of BITC-p on BaP, C.P and MMC induced chromosomal aberrations in bone marrow of mice                                           | 66   |
| 3          | Histogram showing the effect of BITC-p on BaP, C.P and MMC induced chromosomal aberrations in spleen of mice                                                | 67   |
| 4          | Effect of benzyliothiocyanate-prodrug (BITC-p) pretreatment on mitotic activity in mice bone marrow cells treated with mutagenic drugs (BaP, C. P. and MMC) | 69   |
| 5          | Histogram showing the effect of BITC-p on BaP, C.P and MMC induced chromosomal aberrations in spermatocytes of mice                                         | 81   |
| 6          | Histogram showing inhibitory effect of highest dose of benzyliothiocyanate-prodrug on Benzyo(a)Pyrene induced abnormal sperm in mice                        | 86   |